HOME  >  Online journal

Vol.60 No.7 contents

Japanese/English

Full Text of PDF (662K) Article in Japanese

- Case Report -

Five Cases of Large-cell Neuroendocrine Carcinoma of the Lung Treated with Nivolumab

Sayaka Kato¹, Yohei Tsunoda¹, Ryo Kimura¹, Masami Orinaka¹, Shoko Miyamatsu¹, Yoshio Ryuge¹, Shuichi Asano¹, Yukinori Hattori^2
1Department of Respiratory Medicine, ²Department of Pathology Medicine, Japan Community Healthcare Organization, Chukyo Hospital, Japan

---

Background. The efficacy of immune checkpoint inhibitors for the treatment of large-cell neuroendocrine carcinoma of the lung has not been sufficiently investigated. We experienced five cases of large-cell neuroendocrine carcinoma of the lung that were treated with nivolumab. Case. The cases involved five men who were 64-74 years old. Of these, two patients were diagnosed using biopsy specimens obtained via endobronchial ultrasound-guided trans-bronchial needle aspiration, and three were diagnosed using surgical specimens. The programmed death-ligand 1 (PD-L1) tumor expression was high in one patient, and nivolumab was effective only in that patient. Conclusion. We experienced a case of large-cell neuroendocrine carcinoma of the lung that was effectively treated using nivolumab. The PD-L1 expression may be a predictive biomarker for the efficacy of nivolumab treatment in large-cell neuroendocrine carcinoma of the lung. Further studies are needed.
key words: Large-cell neuroendocrine carcinoma, Immune checkpoint inhibitor, Nivolumab

Received: June 4, 2020
Accepted: September 16, 2020

JJLC 60 (7): 1017-1021, 2020